Intellia Therapeutics Files Shelf Prospectus For Offering; Size Not Disclosed
https://www.sec.gov/Archives/edgar/data/1652130/000119312526470525/d150437ds3asr.htm
Follow the latest Intellia Therapeutics, Inc. (NTLA) news and market headlines alongside the live NTLA price. Stay informed on what's moving NTLA.
https://www.sec.gov/Archives/edgar/data/1652130/000119312526470525/d150437ds3asr.htm
U.S. stocks were mixed as Nasdaq fell over 2%; Buckle surged 7.8% on strong results, while Evolent, Gap and others gained.
Intellia Therapeutics announced positive clinical data for lonvo-z, its one-time CRISPR gene editing treatment for hereditary angioedema (HAE), presented at ACAAI 2026. Key findings include an 81% reduction in monthly attack rates for patients previously on long-term prophylaxis, with 100% of patients becoming prophylaxis-free. Patient interviews showed 96% described lonvo-z as optimal therapy. The FDA accepted the BLA with Priority Review and a PDUFA target action date of March 10, 2027.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to NTLA, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.